Dernières informations Corporate et commerciales

Derniers communiqués

Immunoscore® included in ESMO Clinical Practice Guidelines 2020

HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been included in the 2020...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx strengthens its Management Team

  • Stephane Debono, EVP, Diagnostics BU and CEO of HalioDx Inc., is appointed Deputy CEO
  • Philippe Mourere joins the...
 Lire la suite

New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer

  • Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of Oncology
  • Consisten...
 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s investigational first-in-class...

 Lire la suite

COVID-19 Business continuity plan

Considering the recent evolution of the COVID-19 situation, HalioDx has actioned a business continuity plan aimed at...

 Lire la suite

Immune response is now part of the Essential and Desirable Diagnostic Criteria for Colorectal Cancers in the 5th edition of the WHO Classification of Tumours

Lire la suite

IMMUNOSCORE® in Colon Cancer

A new milestone for Immunoscore® in the UK

Five major private medical insurances in the UK cover Immunoscore® test for all their patients with localised colon...

 Lire la suite

OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...

 Lire la suite

See more Press releases